Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
18.16
+0.12 (0.67%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Dyne Therapeutics Employees
Dyne Therapeutics had 258 employees as of December 31, 2025. The number of employees increased by 67 or 35.08% compared to the previous year.
Employees
258
Change (1Y)
67
Growth (1Y)
35.08%
Revenue / Employee
n/a
Profits / Employee
-$1,729,512
Market Cap
3.00B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Denali Therapeutics | 503 |
| Arcutis Biotherapeutics | 354 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Catalyst Pharmaceuticals | 182 |
DYN News
- 1 day ago - Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting - GlobeNewsWire
- 5 days ago - Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 27 days ago - Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - GlobeNewsWire
- 6 weeks ago - Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 7 weeks ago - Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire